# Diego Braguglia

> Diego Braguglia is a Series B investor at VI Partners backing Biotechnology and Health Care. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [VI Partners](https://shizune.co/investors/profile/vi-partners)
- Total investments: 12
- Last investment: Oct 2024
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/diego-braguglia-9634b915/
- Website: https://vipartners.ch/about-us/diego-braguglia/

Diego Braguglia is a Series B investor at VI Partners focused on Biotechnology and Health Care. Diego Braguglia joined VI Partners in January 2003 as a partner focusing on life-science and biotech investments. He brings over 10 years of experience in life science, medical devices and pharmaceuticals in Europe and the US. Prior to his entry into the VC industry Diego has held various managerial positions in the pharmaceuticals and medicaldevices sectors, as well as in biotech start ups in Europe and the US.Diego holds an M. Sc. in Microbiology from the Biocenter of the University of Basel and a Ph.D. in Molecular and Cellular Biology from the Swiss Cancer Research Institute (ISREC) in Lausanne. He is fluent in English, French Italian and German.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 33% |
| Health Care | 3 | 25% |
| Medical Device | 3 | 25% |
| Therapeutics | 2 | 17% |
| Biopharma | 1 | 8% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 33% |
| Series A | 3 | 25% |
| Series C | 2 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 5 | 42% |
| Romania | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Somagenetix | Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases. | $11.7M | Series A | Oct 08, 2024 |  |
| iOnctura | iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $85.7M | Series B | Jun 20, 2024 |  |
| iOnctura | iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $5.8M | Series A | Jul 14, 2020 |  |
| iOnctura | iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $16.5M | Series A | Jan 23, 2020 |  |
| Amal Therapeutics | Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. | $31.8M | Series B | Nov 12, 2018 |  |
| Amal Therapeutics | Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. | $8.8M | Series B | Sep 05, 2017 |  |
| Amal Therapeutics | Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. | $3.5M | Series A | Mar 30, 2016 |  |
| Endosense | Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact forceduring the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation. | $43.6M | Series C | Nov 27, 2013 |  |
| Endosense | Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact forceduring the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation. | $40.3M | Series C | Nov 27, 2012 |  |
| Endosense | Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact forceduring the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation. | $36M | Series B | Oct 27, 2009 |  |

10 of 12 investments shown.

## Co-investors
- [3B Future Health Fund](https://shizune.co/investors/profile/helsinn-investment-fund) — VC Fund, 4 deals together
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 4 deals together
- [Schroder Adveq](https://shizune.co/investors/profile/schroder-adveq) — VC Fund, 4 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 3 deals together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 3 deals together
- [Inkef](https://shizune.co/investors/profile/inkef-capital) — VC Fund, 3 deals together

## About VI Partners

VC Fund · Altendorf, Switzerland

Healthcare & Technology Venture Capital since 2001

5 contacts available at VI Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Arnd Kaltofen | Co-Founder and Managing Partner | https://shizune.co/investors/profile/arnd-kaltofen |
| Cyrill Osterwalder | Principal | https://shizune.co/investors/profile/cyrill-osterwalder |
| Diego Braguglia | General Partner | https://shizune.co/investors/profile/diego-braguglia |
| Olivier Laplace | Partner | https://shizune.co/investors/profile/olivier-laplace |
| Alain Nicod | Co-Founder and Managing Partner | https://shizune.co/investors/profile/alain-nicod |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Diego Braguglia invest in?

Diego Braguglia invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series B and Series A stage. Most of the 12 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Diego Braguglia last invest?

The most recent investment recorded for Diego Braguglia closed in Oct 2024. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co